Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative anti-VEGF injection for prevention of postoperative vitreous rebleeding in proliferative diabetic retinopathy
ChiCTR2000031400Phase 4Recruiting
- Sponsor
- Shanxi Eye Hospital
- Start
- Apr 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab and conbercept in diabetic retinopathy (DR) and proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Shanxi Eye Hospital. Primary endpoints: Incidence of postoperative vitreous hemorrhage and Mean change in best-corrected visual acuity. Started Apr 2020; status: recruiting.
02
Drugs
ranibizumabconbercept
03
Conditions
diabetic retinopathy (DR)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2000031400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031400.